Familial Combined Hyperlipidemia (FCH) Patients with High Triglyceride Levels Present with Worse Lipoprotein Function Than FCH Patients with Isolated Hypercholesterolemia
Puig Grifol, Núria (Universitat Autònoma de Barcelona. Departament de Bioquímica i de Biologia Molecular)
Miñambres, Inka (Institut d'Investigació Biomèdica Sant Pau)
Benitez, Sonia (Institut d'Investigació Biomèdica Sant Pau)
Gil, Pedro (Institut d'Investigació Biomèdica Sant Pau)
Grau-Agramunt, Margarida (Institut d'Investigació Biomèdica Sant Pau)
Rivas-Urbina, Andrea (Institut d'Investigació Biomèdica Sant Pau)
Pérez Pérez, Antonio (Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas)
Sanchez-Quesada, Jose Luis (Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas)

Date:	2020
Abstract:	Lipoprotein characteristics were analyzed in familial combined hyperlipidemia (FCH) patients before and after statin treatment. Twenty-six FCH patients were classified according to the presence (HTG group, n = 13) or absence (normotriglyceridemic (NTG) group, n = 13) of hypertriglyceridemia. Fifteen healthy subjects comprised the control group. Lipid profile, inflammation markers, and qualitative characteristics of lipoproteins were assessed. Both groups of FCH subjects showed high levels of plasma C-reactive protein (CRP), lipoprotein-associated phospholipase A2 (Lp-PLA2) activity and apolipoprotein J. Statins reverted the increased levels of Lp-PLA2 and CRP. Lipoprotein composition alterations detected in FCH subjects were much more frequent in the HTG group, leading to dysfunctional low-density lipoproteins (LDL) and high-density lipoproteins (HDL). In the HTG group, LDL was smaller, more susceptible to oxidation, and contained more electronegative LDL (LDL(-)) compared to the NTG and control groups. Regarding HDL, the HTG group had less Lp-PLA2 activity than the NTG and control groups. HDL from both FCH groups was less anti-inflammatory than HDL from the control group. Statins increased LDL size, decreased LDL(-), and lowered Lp-PLA2 in HDL from HTG. In summary, pro-atherogenic alterations were more frequent and severe in the HTG group. Statins improved some alterations, but many remained unchanged in HTG.
Grants:	Agència de Gestió d'Ajuts Universitaris i de Recerca 2017/SGR-1149
Note:	Altres ajuts: MSCBS/FIS/PI13/00364
Note:	Altres ajuts: MSCBS/FIS/PI16/00471
Rights:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Language:	Anglès
Document:	Article ; recerca ; Versió publicada
Subject:	Familial combined hyperlipidemia ; Lipoproteins ; Lipoprotein function ; Inflammation ; Triglycerides
Published in:	Biomedicines, Vol. 8, Num. 1 (January 2020) , art. 6, ISSN 2227-9059

DOI: 10.3390/biomedicines8010006
PMID: 31935793

16 p, 1.4 MB

The record appears in these collections:
Research literature > UAB research groups literature > Research Centres and Groups (research output) > Health sciences and biosciences > Institut de Recerca Sant Pau
Articles > Research articles
Articles > Published articles